0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CD20 > CDP-H52P6

Human CD20 Full Length Protein-VLP (HEK293)

  • Synonym
    MS4A1,CD20,MS4A-1
  • Source
    Human CD20 Full Length Protein-VLP (CDP-H52P6) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).
    Predicted N-terminus: Met
  • Molecular Characterization

    This protein carries no "tag".

    The protein has a calculated MW of 33.1 kDa.

    Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane proteins (like CD20) can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.

    The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of ~150 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, pH 7.4 with trehalose as protectant.

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
    Contact us for customized product form or formulation.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;

    2. -70°C for 3 months under sterile conditions.

  • Shipping
    This product is supplied and shipped as sterile liquid solution with dry ice, please inquire the shipping cost.
Bioactivity-ELISA
Human CD20 Full Length Protein-VLPHuman CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) ELISA bioactivity

Immobilized Human CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) at 5 μg/mL (100 μL/well) can bind Rituximab with a linear range of 0.3-5 ng/mL (QC tested).

Human CD20 Full Length Protein-VLPHuman CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) ELISA bioactivity

Immobilized Human CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) at 5 μg/mL (100 μL/well) can bind Ofatumumab with a linear range of 0.3-5 ng/mL (QC tested).

Human CD20 Full Length Protein-VLPHuman CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) ELISA bioactivity

Immobilized Human CD20 Full Length Protein-VLP (Cat. No. CDP-H52P6) at 5 μg/mL (100 μL/well) can bind Obinutuzumab with a linear range of 0.2-1 ng/mL (QC tested).

  • Background
    B-lymphocyte antigen CD20  is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.
  • Clinical and Translational Updates

      

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $600.00

Price(USD) : $1200.00

Price(USD) : $3800.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:22 Details
  • Number of Drugs in Clinical Trials:72 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop